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Formulation Unit
 Remit 
To develop novel anti-cancer drugs selected by Cancer Research 
UK New Agents Committee for Phase I and II Clinical Trial
Pharmaceutical Translation Research
 Established in 1983
Bench to Bedside  ?Powder to Product  ?Molecule to Medicine
Pharmaceutical Development
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Manufacture Distribution Clinical Trial
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 Multiple factors
 One goal
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 Early Projects
 Research Advances
 Recent Projects
 Currents Trends
 Potential Answers
Early Example - 1984
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 Many and varied
Exact number unknown
 Small molecules
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Clinical Trials
 1, 2, 4-triglycidyl 
urazol
 Starting Dose
30mg/m2 escalated 
to 900mg/m
 Toxicity
 Myelosuppression
, nausea, 
vomiting, phlebitis
 RH1
 Eligibility 
criteria
Proven cancer, 
refractory to 
treatment, no 
conventional 
therapy, >18 yrs, 
life expectancy >3 
months
Tumour Type No
Colorectal 8
Gastric 3
NSCLC 2
Melanoma 2
Merkel cell 
carcinoma
1
Pancreatic 1
Renal 1
Common Issues
 Pharmacology
Cytotoxic chemotherapy
Limited administration
 Majority of formulations injections
 Drug solubility
Range of formulation techniques applied
 Drug stability
Hydrolytic  ? lyophilisation
Non-hydrolytic  ?physicochemistry
 General trials
Research Advances
 Imatinib  ?2001
 ?ĂǁŶŽĨƚĂƌŐĞƚĞĚƚƌĞĂƚŵĞŶƚƐ ?
Very Different Drugs
sorafenib
nilotinib
imatinib Solubility 200mg/ml
Oral Bioavailability 98% 
Solubility sparingly
Oral Bioavailability 31% 
Solubility (1:2 DMSO:PBS) 0.3mg/ml
Oral Bioavailability 50% 
Intestinal Solubility Variation
 Impact of simulated gastrointestinal fluid composition
Khadra, I., et.al., (2015) Eur. J. Pharm. Sci., 67: 65-75 (Fasted data only)
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Impact on Dissolution
 Low solubility 
Slower dissolution
 Natural GIT variation
 Not applicable
Amorphous
Bioenhanced
But does it stay in 
solution?
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Biopharmaceutics Classification System
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Dissolution Rate
Limited
Solubility
Limited
Impact on pharmacokinetics
 Phase 1 Dose escalation studies  ?BCS I to BCS II
CRUK07/13
Impacts receptor exposure
Bioenhanced Formulations
 Improve dissolution
Amorphous
Solid solutions
 Spring and parachute effect
 Stability
Chemical & Physical
 Solid solution
Drug/Excipient 
Intimate contact
 Excipient Quality
Common Issues
 Pharmacology
Targeted chemotherapy
Single pathway
Continuous administration
 Majority of formulations oral
 Drug solubility  ? impacts on drug absorption
 Bioenhanced formulations
Stability problems
 Targeted trials
Current Trends I
 Smaller patient numbers
 Therapy cost increases
 Combination therapies
 Agile therapy
Rapid changes
Current Trends II
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Pharmaceutical Hockey Stick
Regulation
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Mass Customisation
Mass Customisation
 This is not new!
Future Pharmaceutical  Challenge
Does one formulation and manufacturing technology fit all?
Solutions  ?scaleable, quick, agile, low cost, GMP compliant, patient friendly
Are there other aspects that can change?
Basic and applied research required
3D Printing
Just in time manufacture
Small scale development
Individual patient trials
3D Printing & Injection Moulding
 Hot topic  ?a la mode
± Multiple groups UK and world-wide -
multiple approaches
 Marketed product
± New field
 Multiple areas of research
± Equipment, process, parameters, 
formulation, product
 Future
± Wide open
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Predictive Pharmaceutics
Mixing
API
Wet 
Granulation
Drying
Milling 
Screening
Mixing Tabletting Coating
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Hot Melt 
Extrusion
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Continuous Unit Operations
Unit Operations which 
could be Continuous
Milling 
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Predict, Integrate, Design, Test
Discovery Development Treatment
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